This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Media Contact: Will Johnson. About Oravax Medical. Investor Contact: Robert Schatz. 646) 421-9523.
Virtual ClinicalTrials transcend geographic, mobility and economic barriers. Clinicaltrials are medical research projects involving human participants. However, the costs of conducting a full-scale clinicaltrial can be prohibitive, posing barriers to research for cannabis companies.
New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”. Media Contact: Will Johnson.
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Guy Goodwin appointed Chief Medical Officer and Danielle Schlosser appointed Senior Vice-President, Clinical Innovation. On track to report top-line data by end of 2021.
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.fda.gov/media/131878/download.
Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Some of the more interesting data on the relationship between opioids and medical marijuana for pain management comes from the field of orthopedic surgery. million to 11.4
Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? The cannabis research problem.
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. Media Contact: Will Johnson. Supera-CBD is being developed to address the rapidly growing CBD market, that includes FDA approved drugs and CBD products not currently regulated as a drug. About FTSE Russell.
Professor Johnson also received national media attention for his appearance in the Home Box Office (HBO) original documentary feature, “Addiction”, which won the prestigious Governors Award, a special Emmy Award, from the Academy of Television Arts and Sciences. ” About Ehave, Inc. Ehave, Inc.
The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids. and are difficult to predict. cbdMD, Inc. John Weston. Director of Investor Relations.
COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinicaltrial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Availability of other information about COMPASS Pathways.
In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinicaltrials. Building the Data Backend. CannabisFN.com and CFN Media, have been hired to create awareness. Mental Health Challenges.
I mean duh, with social media, bosses that don’t understand you have a life and the new Bob Dylan documentary on Netflix – how can anyone doze off and dream anymore? And who doesn’t feel that dark cloud of stress, anxiety and drag get bigger when they’re tossing and turning all night? Our health and wellness depends on it!
To understand the breadth of issues and gather data on safety we have conducted a public hearing, reviewed the medical literature, and have an open public docket.”. The FDA is collecting data to fill these gaps. The FDA cautioned that, without prompt action, legal action may follow, including seizure and injunctions.
The presentation details the identification of a novel locus on chromosome 14 which is associated with proteinuric kidney disease and includes data which confirms the well-known association of APOL1 risk haplotypes (i.e., New data supporting the use of machine learning and electronic health records to predict DN in patients with diabetes. “We
Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.
Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinicaltrial for lead kidney precision medicine product candidate GFB-887. Media: Liz Melone.
He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders. Anderson will be responsible for Anebulo’s global investor relations and public relations programs.
At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.
The approval of cannabidiol oral solution is based on results from four randomised, controlled Phase 3 trials. These studies incorporate data from more than 714 patients with either LGS or Dravet syndrome, two rare forms of epilepsy with high morbidity and mortality rates, which place a significant burden on families and caregivers. “The
The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinicaltrial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease. March 31, 2021. ($). .
“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinicaltrial of our lead precision kidney medicine candidate, in mid-2022.”. Media: Liz Melone. 212-362-1200.
1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and [link] External Link Disclaimer ; these websites direct consumers to your website, [link] External Link Disclaimer , to purchase your products. Anxiety, depression, post-traumatic stress disorders, and even schizophrenia.
CP: I’m going to say yes and it’s hard to tie this together, but there’s actually some really good animal, and a little bit of human data to support this. I postulate that that is correlated to our endocannabinoid system, which good data is now suggesting, is dysregulated in metabolic syndrome: obesity, diabetes, heart disease.
The opening of private cannabis clinics in the UK is in response to the British Home Office making medicinal cannabis legal from 1 November 2018, reclassifying it from Schedule 1 to Schedule 2 under the 2001 Misuse of Drugs Regulations. The new legislation permits specialist doctors to legally prescribe cannabis-based medicines.
Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinicaltrials before they can conclude certain products as GRAS. “To
It is important that they conduct medical research into the safety and effectiveness of cannabis products through adequate and well-controlled clinicaltrials. Some states require mandatory warning statements in advertisements for medical cannabis. a playground, recreation centre, library or public park.
Once the Envelta IND-enabling studies are submitted to the FDA, the data may be cross-referenced to our cancer pain and PTSD INDs. Media: Laura Radocaj. About Virpax Pharmaceuticals. Christopher M. Chipman, CPA. Chief Financial Officer. cchipman@virpaxpharma.com 610-727-4597. Betsy Brod. Affinity Growth Advisors. 212-825-3210.
ELE-Psilo program expected to enter clinicaltrials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Media and Investor Contacts For Eleusis: Alex Speiser, Corporate Development Director. Email: alexander.speiser@eleusisltd.com.
The Financing will allow the Company to continue progressing its R&D, clinicaltrials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinicaltrials in early 2022,” said CEO, Josh Bartch. DENVER, Dec. Advancements in IP and Drug Development.
Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. At the same time, the outlook on cannabis research data is largely positive. Media framing of cannabis. Background.
These describe technology and infrastructure for the collection of precise, multimodal, multivalent data that can be processed via machine learning, artificial intelligence, signal processes, and other statistical methods to yield clinically meaningful output to satisfy the requirements of the IFU. Media Contact: media@mindmed.co.
“As MMJ International Holdings continues to advance to its clinicaltrials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.
Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinicaltrial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. Clinical Trials.gov Identifier: NCT03787628 ).
Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com. GREENWOOD VILLAGE, Colo. &
This year, we are completing the second Phase 3 clinicaltrial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Media coverage of the paper led to a new stigma and political pressure ended the Spain MDMA study. Rick Doblin, Ph.D.,
EBRX-101 on Track to Submit Regulatory Package for Human DMT ClinicalTrial. The Company is pleased to confirm that it is on track to submit its regulatory package to the Dutch ethics committee in early 2022 for its upcoming human trial. For more information, please contact the Company at: Entheon Biomedical Corp.
Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.
Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights. Established history of providing ketamine infusion services: The management team at KWC has been in ?
o Technology powered research: Virtual clinicaltrials and other accelerated technologies that mix the potential of new technologies with cannabis to create research insights quickly and more accurately, are being classified as Cannabis 3.0, triggering new innovations and improved data quality through better user experiences.
Continue to explore CBDV in autism through a combination of open-label and investigator-led placebo controlled clinicaltrials with data from one or more of these programs in 2020. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol. Media Enquiries: Sam Brown Inc. media enquiries.
Clinicaltrials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. For further information: For media inquiries: Contact Jonathan McGuire, Assistant Vice President, Corporate Communications, Horizons ETFs Management (Canada) Inc.,
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content